Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec 8;82(1):118–123. doi: 10.1054/bjoc.1998.0887

Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors

T M Proebstle 1, W Jiang 2, J Högel 3, U Keilholz 4, L Weber 2, C Voit 5
PMCID: PMC2363205  PMID: 10638977

Abstract

The clinical value of the reverse transcription polymerase chain reaction (RT-PCR) assay for tyrosinase in peripheral blood of melanoma patients is still under debate. A total of 212 blood samples from 212 melanoma patients in all clinical stages (AJCC) were examined. Erythrocytes were lysed prior to RNA extraction by phenol precipitation from 2.7 ml of blood. cDNA for tyrosinase PCR was synthesized using random hexamers. Positive tyrosinase RT-PCR results were obtained in 11% of 106 stage I patients, 18% of 56 stage II patients, 31% of 26 stage III patients and 67% of 24 stage IV patients. After a median follow-up of 36 months (range 26–41), stage III patients with positive RT-PCR for tyrosinase had a shortened disease-free interval as compared to negative patients (P< 0.01). In stage IV patients, median overall survival was 8 months in case of a positive RT-PCR in contrast to 12 months in case of a negative test. While univariate analysis showed sex and primary tumour location associated with positive RT-PCR, multiple regression analysis revealed clinical stage and detection of tyrosinase transcripts in peripheral blood as best prognostic factors. Hazard ratios for disease-free survival were 19.7 (confidence interval (CI) 8.53–45.5, P = 0.0001) for metastatic vs primary disease and 2.96 (Cl 1.49–5.89, P = 0.002) for positive vs negative tyrosinase RT-PCR. The corresponding hazard ratios for overall survival were 97.0 (Cl 12.7–741, P = 0.0001) and 4.33 (Cl 1.69–11.1, P = 0.002). Our results emphasize the importance of tyrosinase RT-PCR testing in peripheral blood. © 2000 Cancer Research Campaign

Keywords: circulating tumour cells, minimal residual disease

Full Text

The Full Text of this article is available as a PDF (86.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battayani Z., Grob J. J., Xerri L., Noe C., Zarour H., Houvaeneghel G., Delpero J. R., Birmbaum D., Hassoun J., Bonerandi J. J. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol. 1995 Apr;131(4):443–447. [PubMed] [Google Scholar]
  2. Brossart P., Keilholz U., Scheibenbogen C., Möhler T., Willhauck M., Hunstein W. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):38–41. doi: 10.1097/00002371-199401000-00005. [DOI] [PubMed] [Google Scholar]
  3. Brossart P., Keilholz U., Willhauck M., Scheibenbogen C., Möhler T., Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol. 1993 Dec;101(6):887–889. doi: 10.1111/1523-1747.ep12371713. [DOI] [PubMed] [Google Scholar]
  4. Farthmann B., Eberle J., Krasagakis K., Gstöttner M., Wang N., Bisson S., Orfanos C. E. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol. 1998 Mar;110(3):263–267. doi: 10.1046/j.1523-1747.1998.00131.x. [DOI] [PubMed] [Google Scholar]
  5. Foss A. J., Guille M. J., Occleston N. L., Hykin P. G., Hungerford J. L., Lightman S. The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer. 1995 Jul;72(1):155–159. doi: 10.1038/bjc.1995.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ghossein R. A., Coit D., Brennan M., Zhang Z. F., Wang Y., Bhattacharya S., Houghton A., Rosai J. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res. 1998 Feb;4(2):419–428. [PubMed] [Google Scholar]
  7. Gläser R., Rass K., Seiter S., Hauschild A., Christophers E., Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol. 1997 Aug;15(8):2818–2825. doi: 10.1200/JCO.1997.15.8.2818. [DOI] [PubMed] [Google Scholar]
  8. Hoon D. S., Wang Y., Dale P. S., Conrad A. J., Schmid P., Garrison D., Kuo C., Foshag L. J., Nizze A. J., Morton D. L. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995 Aug;13(8):2109–2116. doi: 10.1200/JCO.1995.13.8.2109. [DOI] [PubMed] [Google Scholar]
  9. Jung F. A., Buzaid A. C., Ross M. I., Woods K. V., Lee J. J., Albitar M., Grimm E. A. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug;15(8):2826–2831. doi: 10.1200/JCO.1997.15.8.2826. [DOI] [PubMed] [Google Scholar]
  10. Keilholz U., Willhauck M., Rimoldi D., Brasseur F., Dummer W., Rass K., de Vries T., Blaheta J., Voit C., Lethé B. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer. 1998 Apr;34(5):750–753. doi: 10.1016/s0959-8049(97)10105-8. [DOI] [PubMed] [Google Scholar]
  11. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  12. Kwon B. S., Haq A. K., Pomerantz S. H., Halaban R. Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7473–7477. doi: 10.1073/pnas.84.21.7473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mellado B., Colomer D., Castel T., Muñoz M., Carballo E., Galán M., Mascaró J. M., Vives-Corrons J. L., Grau J. J., Estapé J. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol. 1996 Jul;14(7):2091–2097. doi: 10.1200/JCO.1996.14.7.2091. [DOI] [PubMed] [Google Scholar]
  14. Ponnazhagan S., Hou L., Kwon B. S. Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. J Invest Dermatol. 1994 May;102(5):744–748. doi: 10.1111/1523-1747.ep12376924. [DOI] [PubMed] [Google Scholar]
  15. Proebstle T. M., Huber R., Sterry W. Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer. 1996 Sep;32A(10):1664–1667. doi: 10.1016/0959-8049(95)00534-x. [DOI] [PubMed] [Google Scholar]
  16. Reinhold U., Lüdtke-Handjery H. C., Schnautz S., Kreysel H. W., Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol. 1997 Feb;108(2):166–169. doi: 10.1111/1523-1747.ep12333341. [DOI] [PubMed] [Google Scholar]
  17. Schwürzer-Voit M., Proebstle T. M., Sterry W. Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients. Eur J Cancer. 1996 Feb;32A(2):264–268. doi: 10.1016/0959-8049(95)00503-x. [DOI] [PubMed] [Google Scholar]
  18. Smith B., Selby P., Southgate J., Pittman K., Bradley C., Blair G. E. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991 Nov 16;338(8777):1227–1229. doi: 10.1016/0140-6736(91)92100-g. [DOI] [PubMed] [Google Scholar]
  19. Van der Velde-Zimmermann D., Roijers J. F., Bouwens-Rombouts A., De Weger R. A., De Graaf P. W., Tilanus M. G., Van den Tweel J. G. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol. 1996 Sep;149(3):759–764. [PMC free article] [PubMed] [Google Scholar]
  20. Wang X., Heller R., VanVoorhis N., Cruse C. W., Glass F., Fenske N., Berman C., Leo-Messina J., Rappaport D., Wells K. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994 Dec;220(6):768–774. doi: 10.1097/00000658-199412000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES